Guideline‑Directed Management of Severe Uncontrolled Systolic Hypertension

1. Assessment of Current Therapy

Beta‑blocker + calcium‑channel blocker (CCB) regimens are not first‑line for uncomplicated hypertension, especially in patients > 60 years, and provide inferior stroke prevention compared with other drug classes (Canadian Cardiovascular Society). Class IIa, Level B 3
The 2025 American Heart Association/American College of Cardiology (AHA/ACC) guidelines state that optimal initial two‑drug therapy should pair a renin‑angiotensin system (RAS) blocker (ACE‑I or ARB) with either a CCB or a thiazide‑type diuretic; a β‑blocker + CCB combination is not recommended. Class I, Level A 1
A systolic blood pressure (SBP) of 191 mm Hg qualifies as severe, uncontrolled hypertension and mandates immediate therapy intensification to avert stroke, myocardial infarction, and end‑stage renal disease. Class I, Level A 1

Add a thiazide‑like diuretic (chlorthalidone 12.5–25 mg once daily or indapamide 1.25–2.5 mg once daily) as a third agent to achieve guideline‑concordant three‑drug therapy. Class I, Level A 1
Thiazide‑like diuretics are superior to hydrochlorothiazide for blood‑pressure reduction and cardiovascular protection in resistant hypertension. Class I, Level A 2
This creates a guideline‑recommended three‑drug regimen of CCB + β‑blocker + thiazide‑like diuretic for patients requiring rapid intensification. Class IIa, Level B 5

If target BP is not reached within 3 months, replace the β‑blocker with an ACE inhibitor (e.g., lisinopril 10–20 mg daily) or an ARB (e.g., losartan 50–100 mg daily) to form the preferred combination: RAS blocker + CCB + thiazide‑like diuretic. Class I, Level A 1
The RAS‑blocker + CCB + thiazide combination provides synergistic BP reduction and yields superior cardiovascular outcomes compared with other three‑drug mixes. Class I, Level A 5

If BP remains uncontrolled on three optimally dosed agents, add spironolactone 25–50 mg daily (provided estimated glomerular filtration rate ≥ 45 mL/min/1.73 m² and serum potassium < 5.0 mmol/L). Class I, Level A 1
When spironolactone is contraindicated, consider amiloride, doxazosin, or clonidine as alternative fourth‑line agents. Class IIa, Level B 1

Target BP: < 130/80 mm Hg for most adults, with individualization based on age and frailty. Class I, Level A 1
Re‑assessment: check office BP 2–4 weeks after adding the diuretic and aim to achieve target BP within 3 months. Class I, Level B 5
Laboratory monitoring: measure serum potassium and creatinine 1–2 weeks after initiating a thiazide‑like diuretic to detect hypokalemia or renal dysfunction. Class I, Level B 4

Avoid dual RAS blockade (simultaneous ACE‑I + ARB) because it increases cardiovascular and renal risk without added benefit. Class III, Level A 4
Screen for secondary hypertension when BP remains resistant to three‑drug therapy at optimal doses, especially in older patients with severe hypertension. Class IIa, Level B 1
Review concomitant medications (e.g., NSAIDs, decongestants, stimulants) that may elevate BP and discontinue them when possible. Class IIa, Level B 1
Promote adherence by instructing patients to take all antihypertensive agents at the same time each day. Class IIa, Level C 7